Strong Performance and Growth Potential Drive Buy Rating for PROCEPT BioRobotics

Morgan Stanley analyst Patrick Wood has maintained their bullish stance on PRCT stock, giving a Buy rating today.

Patrick Wood has given his Buy rating due to a combination of factors that highlight PROCEPT BioRobotics’ strong performance and potential for future growth. The company reported a solid start to the year with a significant sales beat in the first quarter, driven by both domestic and international markets. This performance was particularly notable in the U.S., where procedural utilization reached an all-time high, indicating strong demand and effective system deployment.
Moreover, PROCEPT BioRobotics raised its 2025 sales guidance, suggesting confidence in continued growth and operational efficiency. The company’s gross margins also exceeded expectations, reflecting improved operational efficiencies and higher average selling prices. These positive financial indicators, alongside the potential for further upside revisions throughout the year, underpin Patrick Wood’s optimistic outlook and Buy rating for the stock.